Resting and exercise-induced IL-6 levels in children with Type 1 diabetes reflect hyperglycemic profiles during the previous 3 days

Journal of Applied Physiology

Volumn 108, Issue 2, 2010, Pages 334-342

  Rosa, Jaime S ^a   Flores, Rebecca L ^a   Oliver, Stacy R ^a   Pontello, Andria M ^a   Zaldivar, Frank P ^a   Galassetti, Pietro R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Exercise; Glucose monitoring; Hyperglycemia; Interleukin 6

Indexed keywords

INTERLEUKIN 6;

ADOLESCENT; AGING; ANAEROBIC THRESHOLD; ARTICLE; BLOOD; CHILD; COHORT ANALYSIS; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; PHYSIOLOGY; REST;

ADOLESCENT; AGING; ANAEROBIC THRESHOLD; BLOOD GLUCOSE; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; EXERCISE; FEMALE; HUMANS; HYPERGLYCEMIA; INTERLEUKIN-6; MALE; REST;

EID: 75749125008     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01083.2009     Document Type: Article

References (50)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 32: S62-S67, 2009.
2. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1-9, 1999. (Pubitemid 29019345)
3. Boucher J, Castan-Laurell I, Daviaud D, Guigne C, Buleon M, Carpene C, Saulnier-Blache JS, Valet P. Adipokine expression profile in adipocytes of different mouse models of obesity. Harm Metab Res 37: 761-767, 2005. (Pubitemid 43028079)
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001. (Pubitemid 34000785)
5. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brownlee M, Gurtner GC. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 283: 10930-10938, 2008.
6. Cesari M, Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. Circulation 108: 2317-2322, 2003. (Pubitemid 37413536)
7. Colbert LH, Davis JM, Essig DA, Ghaffar A, Mayer EP. Tissue expression and plasma concentrations of TNF-a, IL-1b, and IL-6 following treadmill exercise in mice. Int J Sports Med 22: 261-267, 2001. (Pubitemid 32476604)
8. Cooper DM, Nemet D, Galassetti P. Exercise, stress, and inflammation in the growing child: from the bench to the playground. Curr Opin Pediatr 16: 286-292, 2004. (Pubitemid 38680448)
9. CooperDM,Weiler-RavellD,WhippBJ,WassermanK. Aerobicparametersofexerciseasafunctionofbodysizeduringgrowthinchildren. JApplPhysiol56:628-634,1984.(Pubitemid14149470)
10. Degerstrom J, Osterud B. Increased inflammatory response of blood cells to repeated bout of endurance exercise. Med Sci Sports Exerc 38: 1297-1303, 2006.
11. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1. diabetes. Diabetes 55: 774-779, 2006.
12. Diabetes Research in Children Network (DIRECNET) Study Group. The accuracy of the CGMS in children with, type 1. diabetes: results of the diabetes research in children network (DirecNet) accuracy study. Diabetes Technol Ther 5: 781-789, 2003.
13. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205: 2409-2417, 2008.
14. Eliakim A, Nemet D, Zaldivar F, McMurray RG, Culler FL, Galassetti P, Cooper DM. Reduced exercise-associated response of the GHIGF-I axis and catecholamines in obese children and adolescents. J Appl Physiol 100: 1630-1637, 2006.
15. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106: 2067-2072, 2002. (Pubitemid 35192812)
16. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel, factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53: 1643-1648, 2004. (Pubitemid 38864744)
17. GalassettiP,TateD,NeillRA,MorreyS,WassermanDH,DavisSN. Effectofantecedenthypoglycemiaoncounterregulatoryresponses- subsequenteuglycemicexerciseintype1diabetes.Diabetes52:17611769,2003. (Pubitemid36792468)
18. Galassetti P, Tate D, Neill RA, Richardson A, Leu SY, Davis SN. Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab 290: E1109-E1117, 2006. (Pubitemid 43847893)
19. Galassetti PR, Iwanaga K, Crisotomo M, Zaldivar FP, Larson J, Pescatello A. Inflammatory cytokine, growth factor and counterregulatory responses to exercise in children with type 1 diabetes and healthy controls. Pediatr Diabetes 7: 16-24, 2006. (Pubitemid 43732637)
20. Galassetti PR, Iwanaga K, Pontello AM, Zaldivar FP, Flores RL, Larson JK. Effect of prior hyperglycemia on IL-6 responses to exercise in children with type 1 diabetes. Am J Physiol Endocrinol Metab 290: E833-E839, 2006.
21. Gillespie KM. Type 1 diabetes: pathogenesis and prevention. Can Med Assoc J' 175: 165-170, 2006.
22. GiuglianoD,CerielloA.Oxidativestressanddiabeticvascularcomplications. DiabetesCare19:257-267,1996.(Pubitemid26070354)
23. Gordin D, Forsblom C, Ronnback M, Parkkonen M, Waden J, Hietala K, Groop PH. Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes. Ann Med 40: 627-633, 2008.
24. Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 18: 992-994, 2004. (Pubitemid 39561502)
25. HuberSA,SakkinenP,ConzeD,HardinN,TracyR.Interleukin- 6exacerbatesearlyatherosclerosisinmice.ArteriosclerThrombVaseBiol19:2364-2367, 1999.(Pubitemid29477837)
26. Johansen J, Harris A, Rychly D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical, practice. Cardiovasc Diabetol 4: 5, 2005. (Pubitemid 41460764)
27. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54: S114-S124, 2005. (Pubitemid 43343339)
28. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526, 2007. (Pubitemid 46588416)
29. LindmarkE,DiderholmE,WallentinL,SiegbahnA. Relationshipbetweeninterleukin6andmortalityinpatientswithuns tablecoronaryarterydisease:effectsofanearlyinvasiveornoninvasivestrategy. JAMA286:2107-2113,2001.(Pubitemid34041595)
30. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 25: 1032-1037, 1998.
31. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 53: 875-883, 2009.
32. Muniandy S, Qvist R, Ong Siok Yan G, Jack Bee C, Koon Chu Y, Vinsent Rayappan A. The oxidative stress of hyperglycemia and the inflammatory process in endothelial cells. J Med Invest 56: 6-10, 2009.
33. Nemet D, Oh Y, Kim HS, Hill M, Cooper DM. Effect of intense exercise on inflammatory cytokines and growth mediators in adolescent boys. Pediatrics 110: 681-689, 2002.
34. Nieman DC, Davis JM, Henson DA, Gross SJ, Dumke CL, Utter AC, Vinci DM, Carson JA, Brown A, McAnulty SR, McAnulty LS, Triplett NT. Muscle cytokine mRNA changes after 2.5 h of cycling: influence of carbohydrate. Med Sci Sports Exerc 37: 1283-1290, 2005. (Pubitemid 41209281)
35. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 117: 1162-1172, 2000.
36. Pedersen BK, Akerstrom TCA, Nielsen AR, Fischer CP. Role of myokines in exercise and metabolism. J Appl Physiol 103: 1093-1098, 2007.
37. Petersen AC, Crockett L, Richards M, Boxer A. A self-report measure of pubertal status: reliability, validity, and initial norms. J Youth Adolesc 17: 117-133, 1988.
38. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl. Physiol 98: 1154-1162, 2005.
39. Pfleger C, Mortensen HB, Hansen L, Herder C, Roep BO, Hoey H, Aanstoot HJ, Kocova M, Schloot NC. Association of IL-lra and adiponectin with C-peptide and remission, in patients with type 1. diabetes. Diabetes 57: 929-937, 2008.
40. Robertson K, Adolfsson P, Riddell MC, Scheiner G, Hanas R. Exercise in children and adolescents with diabetes. Pediatr Diabetes 9: 65-77, 2008.
41. Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP, Galassetti PR. Sustained IL, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr Diabetes 9: 9-16, 2008.
42. Rosa JS, Schwindt CD, Oliver SR, Leu SY, Flores RL, Galassetti PR. Exercise leukocyte profiles in healthy, type 1 diabetic, overweight, and asthmatic children. Pediatr Exerc Sci 21: 19-33, 2009.
43. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1. diabetes: the EURODIAB prospective complications study. Diabetes Care 26: 2165-2173, 2003. (Pubitemid 41184269)
44. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 53: 2079-2086, 2004. (Pubitemid 38970758)
45. The Diabetes Control and Complications Trial (DCCT)/The Epidemiology of Diabetes Interventions and Complications (EDIC) Research Groups. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). Pediatrics .139: 804-812, 2001.
46. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
47. The Diabetes Control, and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389, 2000.
48. The Diabetes Control, and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653, 2005.
49. Willemsen JM, Westerink JW, Dallinga-Thie GM, van Zonneveld AJ, Gaillard CA, Rabelink TJ, de Koning EJ. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes. J Cardiovasc Pharmacol 49: 6-12, 2007.
50. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11: 2279-2299, 2005. (Pubitemid 40872698)